JPMorgan Mid Cap Growth benefits from capable leadership, solid analytical support, and a sensible, risk-aware approach. It earns a Process rating upgrade to Above Average from Average.
This strategy leverages an accomplished growth team and competent lead manager; Felise Agranoff guides this strategy and brings experience across the market-cap spectrum. She has managed this mid-cap growth strategy for more than a decade, previously comanaged the firm’s small-cap growth fund for six years, and has experience in large-cap portfolio management.
Comanager Mike Stein helps Agranoff keep a pulse on small-cap ideas. Stein has served as a comanager on JPMorgan Small Cap Growth since 2023 and will step into a lead role when its longtime lead manager steps off at the end of July 2026. Together, they benefit from the support of J.P. Morgan’s experienced small/mid-cap and large-cap growth research analyst teams.
Agranoff’s philosophy is consistent with the firm’s broader growth platform. Her team seeks companies with underappreciated growth prospects and durable competitive advantages that can drive earnings growth over the next three to five years. At the same time, the process is more benchmark-aware than those of many mid-growth peers. The managers carefully consider benchmark risk when sizing positions and incorporate near-term analysis to assess expectations embedded in stock prices, helping to mitigate some of the risks associated with a growth-oriented portfolio.
The recent environment has been challenging for active mid-cap growth managers—including Agranoff and her colleagues. Benchmark returns in 2023 and 2024 were heavily influenced by the outsize gains of Palantir Technologies and AppLovin, making it difficult for many active strategies to keep pace. While this strategy added those names to the portfolio, it still lagged the benchmark by roughly 5 percentage points annualized over that two-year period. It did fare better than some peers that completely avoided the companies, though. Performance improved in 2025, however, and continued to rebound in the first half of 2026, when the strategy outperformed the index by 2.4 percentage points, aided by strong stock selection in technology names such as Ciena and Teradyne.
Overall, this strategy’s various strengths make it a compelling option.